Abstract: A process for partial dehydration of a gas by contact with a solvent that can be regenerated by: a) A stage for absorption of H2O by contact of the gas to be treated and regenerated solvent producing a dehydrated gas effluent and a liquid solvent effluent that is charged with H2O and absorbed gas, b) A stage for cooling the solvent charged with H2O at ambient temperature, c) A stage for separation by segregation during which liquid H2O and the solvent are separated at ambient temperature, d) A stage in which the regenerated solvent that is obtained at the end of stage c) is heated, e) A stage in which the regenerated and heated solvent that is obtained at the end of stage d) is recycled to the absorption stage a).
Abstract: The invention relates to an illumination unit having an adjustable color location consisting of a discharge lamp as primary light source and LEDs as secondary light source and additionally a phosphor layer in the form of a phosphor screen comprising conversion phosphors. Furthermore, the present invention relates to a method for lighting usable areas by the illumination unit according to the invention.
Type:
Grant
Filed:
April 18, 2008
Date of Patent:
September 4, 2012
Assignee:
Merck Patent Gesellschaft Mit Beschrankter Haftung
Abstract: To provide functional paste with etching activity and good electrical properties. Functional paste comprising a metal powder, an etching agent, a binder and an organic solvent.
Type:
Grant
Filed:
October 22, 2004
Date of Patent:
September 4, 2012
Assignee:
Merck Patent GmbH
Inventors:
Sylke Klein, Armin Kuebelbeck, Werner Stockum, Jun Nakanowatari, Kiyohiko Kawamoto, Katsumi Tanino
Abstract: For selective treatment of diseased tissue sections or organ parts, the surface of medical devices entering into contact with areas thereof under pressure is coated with lipophilic substantially water-insoluble medicaments binding to various tissue components with good adherence thereto, said medicaments having an effect thereupon a short time after entering into contact therewith without exerting a harmful influence upon adjacent healthy tissue.
Abstract: Novel compounds of the formula I, in which X, Y, R, R?, R1, R1?, R1?, R2, R2?, R2?, R3, R3?, R4, R4? and n have the meanings indicated in Patent Claim 1, are suitable as antidiabetics
Type:
Grant
Filed:
May 25, 2007
Date of Patent:
September 4, 2012
Assignee:
Merck Patent GmbH
Inventors:
Werner Mederski, Norbert Beier, Bertram Cezanne, Rolf Gericke, Markus Klein, Christos Tsaklakidis
Abstract: The invention relates to a catalyst that comes in the form of grains, each grain consisting of a core covered by at least one external layer, the core consisting of an acidic porous solid and having a size of between 0.1 micron and 0.4 millimeter, in which the external layer has a uniform thickness with a uniformity criterion C, which is less than 0.30, whereby said uniformity criterion C is defined as being equal to an average, on a number N of catalyst grain samples, of the ratio of the difference between the maximum thickness, Eimax, of the external layer and the minimum thickness, Eimin, of this same layer to the average of these two thicknesses Eimax and Eimin.
Type:
Grant
Filed:
January 13, 2005
Date of Patent:
September 4, 2012
Assignee:
IFP Energies nouvelles
Inventors:
Younes Bouizi, Valentin Valtchev, Loiec Rouleau, Nicolas Bats, Laurent Simon
Abstract: The present invention relates generally to the field of ligands for nicotinic acetylcholine receptors (nAChR), activation of nAChRs, and the treatment of disease conditions associated with defective or malfunctioning nicotinic acetylcholine receptors, especially of the brain. Further, this invention relates to novel compounds (indazoles and benzothiazoles), which act as ligands for the ?7 nAChR subtype, methods of preparing such compounds, compositions containing such compounds, and methods of use thereof.
Abstract: Disclosed herein, in certain embodiments, is a crystalline polymorph form A of N—(S)-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide. Further disclosed herein, in certain embodiments, are pharmaceutical compositions comprising the crystalline polymorph form A of N—(S)-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide.
Abstract: A seat track mechanism for a vehicle, includes a lower rail mounted to a vehicle floor; an upper rail supported by the lower rail and slidable relative to the lower rail; and spherical rotators held between the lower and upper rails, the spherical rotators rolling via a sliding movement of the upper rail. One of the upper rail and the lower rail includes at least one horizontal flat portion parallel to a widthwise direction of the seat track mechanism and parallel to a direction of the sliding movement of the upper rail, and the other of the upper rail and the lower rail includes at least one rotator supporting recess having a circularly arcuate shape in cross section which is uniform in a lengthwise direction of the seat track mechanism, the spherical rotators being held between the rotator supporting recess and the horizontal flat portion.
Type:
Grant
Filed:
July 9, 2008
Date of Patent:
August 28, 2012
Assignee:
Shiroki Corporation
Inventors:
Akihiro Kimura, Hidehiko Fujioka, Hiroyuki Suzuki, Kanji Yamaguchi
Abstract: The invention relates to novel mesogenic dimeric compounds which are especially suitable for use in birefringent films with negative optical dispersion, to novel liquid crystal (LC) formulations and polymer films comprising them, and to the use of the dimers, formulations and films in optical, electrooptical, electronic, semiconducting or luminescent components or devices.
Type:
Grant
Filed:
August 29, 2008
Date of Patent:
August 28, 2012
Assignee:
Merck Patent Gesellschaft mit Beschränkter Haftung
Inventors:
Kevin Adlem, Owain Llyr Parri, Karl Skjonnemand, David Wilkes
Abstract: The present invention relates to butenoic acid derivatives of the formula I: in which R, R1, R2 and R3 are as defined in the description, and also to processes for the preparation thereof, to pharmaceutical compositions comprising them and to their use for the treatment of dyslipidaemia, atherosclerosis and diabetes.
Type:
Grant
Filed:
June 23, 2010
Date of Patent:
August 21, 2012
Assignee:
Merck Patent GmbH
Inventors:
Jean-Jacques Zeiller, Hervé Dumas, Valérie Guyard-Dangremont, Isabelle Berard, Francis Contard, Daniel Guerrier, Gérard Ferrand, Yves Bonhomme
Abstract: Process for the production of a hydrocarbon fraction with a high octane number and a low sulfur content from a hydrocarbon feedstock, comprising at least the following stages: 1) a hydrodesulfurization stage of the hydrocarbon feedstock, and 2) at least one stage for extracting aromatic compounds on all or part of the effluent that is obtained from the hydrodesulfurization stage, whereby said extraction leads to a paraffin-enriched raffinate and an aromatic compound-enriched extract sent to a gasoline pool to improve its octane number, wherein a portion of the paraffinic raffinate can be used in a mixture with the aromatic extract; another portion can be used as a petrochemistry base either for producing aromatic compounds or for producing olefins.
Type:
Grant
Filed:
May 26, 2009
Date of Patent:
August 21, 2012
Assignee:
IFP Energies Nouvelles
Inventors:
Quentin Debuisschert, Jacinthe Frecon, Robert L. Huggins
Abstract: The present invention provides a method of treating scleroderma. The method consists in the upregulation of miR-29 by administration of miR-29 or a miR-29 upregulator which elevates circulating and/or intracellular concentrations of miR-29. The invention likewise relates to the use of miR-29 for such a treatment, and the use of miR-29 for the manufacture of a medicament for the treatment of scleroderma.
Type:
Grant
Filed:
September 4, 2009
Date of Patent:
August 21, 2012
Assignee:
Universitat Zurich Prorektorat MNW
Inventors:
Steffen Gay, Oliver Distler, Britta Maurer
Abstract: A system for use in one-way communications takes data from a source and parses it into work units. The work units may have a fixed size. The data of the work units is given to a redundant array of independent disks (RAID) library. The RAID library applies parity to the data and produces a number of output streams. Each stream includes data from the work units and redundant data from the parity application. The streams are combined and sent over a network. The inverse parity is applied on the receiving side to recreate the data. The redundant data is used in place of any data having an error condition, such as being lost or corrupted. The data is reconstructed on the receiving end without the need to resend data.
Type:
Grant
Filed:
September 2, 2008
Date of Patent:
August 21, 2012
Assignee:
Ambriel Technologies, LLC.
Inventors:
Samuel A. Moats, Stephen J. Grassi, Oscar F. Roeder, Faith Power
Abstract: Compounds of Formula I that inhibit Btk are described herein. Pharmaceutical compositions comprising at least one compound of Formula I, together with at least one pharmaceutically acceptable vehicle chosen from carriers, adjuvants, and excipients, are described. Methods of treating patients suffering from certain diseases responsive to inhibition of Btk activity and/or B-cell activity are described. Methods for determining the presence of Btk in a sample are described.
Type:
Grant
Filed:
November 4, 2010
Date of Patent:
August 21, 2012
Assignee:
Gilead Connecticut, Inc.
Inventors:
Peter A. Blomgren, Kevin S. Currie, Seung H. Lee, Scott A. Mitchell, Jianjun Xu, Aaron C. Schmitt, Zhongdong Zhao, Pavel E. Zhichkin, Douglas G. Stafford, Jeffrey E. Kropf
Abstract: The invention concerns a process for preparing a hybrid organic-inorganic material (HOIM) with phosphorus-containing bridges between the surface of an inorganic substrate containing an element M and one or more organic groups of the covalent M-O-P-R type, said process using, as a precursor for said organic group or groups, at least one organophosphorus acid halide with formula RxP(O)Xy in which x=1 or 2, y=3?x, X being a halogen and R designating at least one organic alkyl, aryl or aryl-alkyl group. Non-exhaustive applications for the hybrid organic-inorganic material obtained by the process of the invention are in the fields of anti-corrosion, lubrication, microelectronics, nanotechnologies, composite materials, heterogeneous catalysis, supported catalysis, depollution and biomedical applications.
Abstract: The invention relates to compounds of formula 1, the production and use thereof as a medicament for the treatment of diseases, particularly tumours and/or diseases caused, mediated or propagated by angiogenesis. The compounds of formula 1 are effective inhibitors of tyrosin kinases, particularly TIE-2 and VEGFR, and Raf-kinases.
Type:
Grant
Filed:
September 1, 2004
Date of Patent:
August 14, 2012
Assignee:
Merck Patent GmbH
Inventors:
Wolfgang Stähle, Alfred Jonczyk, Wilfried Rautenberg
Abstract: Provided are a polycarbonate resin which can solve problems present in an electrophotographic photoreceptor and an electrophotographic photoreceptor in which the above polycarbonate resin is used and which is improved in a cleaning property, a lubricity and an abrasion resistance. The polycarbonate resin comprises a repetitive unit represented by the following Formula (1), and the electrophotographic photoreceptor in which a photosensitive layer is provided on a conductive substrate contains the above polycarbonate resin in the above photosensitive layer. In the following Formula (1), R represents an alkyl group having 1 to 3 carbon atoms; n1 is an integer of 2 to 4; and n2 is an integer of 1 to 200.